Intellia Therapeutics, Inc. NGM · NTLA
Price alert —
Sign in to get a one-time email the moment NTLA crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · NTLA
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.0B | $-0.1B | $-0.1B | $-0.1B | -639.5% | -668.1% |
| 2025-12-31 | $0.0B | $-0.1B | $-0.1B | $-0.1B | -416.2% | -428.9% |
| 2025-09-30 | $0.0B | $-0.1B | $-0.1B | $-0.1B | -735.2% | -808.9% |
| 2025-06-30 | $0.0B | $-0.1B | $-0.1B | $-0.1B | -710.8% | -772.2% |
| 2025-03-31 | $0.0B | $-0.1B | $-0.1B | $-0.1B | -687.6% | -726.6% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare NTLA vs peers
Line NTLA up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with NTLA
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-11 | -0.81 | -0.90 | +9.8% | -3.0% |
| 2026-02-26 | -0.83 | -0.96 | +13.7% | -3.5% |
| 2025-11-06 | -0.92 | -0.98 | +6.6% | -22.7% |
| 2025-08-07 | -0.98 | -1.01 | +2.5% | -5.8% |
| 2025-05-08 | -1.10 | -1.27 | +13.5% | -1.9% |
| 2025-02-27 | -1.27 | -1.32 | +3.5% | -7.1% |
| 2024-11-07 | -1.34 | -1.37 | +2.1% | +4.6% |
| 2024-08-08 | -1.52 | -1.20 | -27.0% | -4.1% |
| 2024-05-09 | -1.12 | -1.36 | +17.7% | -1.6% |
| 2024-02-22 | -1.46 | -1.44 | -1.7% | -4.0% |
| 2023-11-09 | -1.38 | -1.50 | +8.2% | -3.3% |
| 2023-08-03 | -1.40 | -1.33 | -5.4% | +1.3% |
| 2023-05-04 | -1.17 | -1.38 | +15.3% | +0.6% |
| 2023-02-23 | -1.38 | -1.37 | -0.4% | -3.2% |
| 2022-11-03 | -1.49 | -1.25 | -18.9% | -1.3% |
| 2022-08-04 | -1.33 | -1.30 | -2.4% | -3.2% |
| 2022-05-05 | -1.96 | -1.11 | -76.4% | -4.9% |
| 2022-02-24 | -1.09 | -0.94 | -16.3% | +10.2% |
| 2021-11-04 | -0.97 | -0.85 | -14.1% | +1.1% |
| 2021-08-05 | -1.01 | -0.61 | -66.0% | +1.3% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| NTLA ★ | $2B | — | -6.3 | 23.5 | -3.2 | 2.2 | — | -9.5% | — | -15.13% |
| LLY | $1,037B | 41.4 | 25.9 | — | 30.0 | 33.3 | 82.8% | 55.5% | 169.9% | 0.88% |
| UNH | $392B | 32.5 | 19.2 | 0.9 | 18.1 | 3.7 | 19.5% | 0.4% | 61.5% | 5.81% |
| JNJ | $615B | 29.7 | 19.9 | 6.3 | 18.3 | 7.6 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 35.9 | 13.2 | — | 12.0 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $448B | 123.6 | 15.6 | 7.1 | 17.2 | -67.2 | 72.0% | 12.4% | -46.2% | 4.65% |
| PFE | $142B | 19.0 | 8.8 | — | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.75% |
| TMO | $196B | 29.0 | 19.3 | — | 20.8 | 3.8 | 40.9% | 6.2% | 11.3% | 2.82% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 46.2%
| Holder | Shares | % out |
|---|---|---|
| ARK Investment Management, LLC | 14,509,247 | 10.38% |
| Blackrock Inc. | 12,155,806 | 8.70% |
| State Street Corporation | 6,922,676 | 4.95% |
| Vanguard Portfolio Management LLC | 6,223,325 | 4.45% |
| Shaw D.E. & Co., Inc. | 5,728,177 | 4.10% |
| Vanguard Capital Management LLC | 5,084,105 | 3.64% |
| Two Sigma Investments, LP | 4,705,901 | 3.37% |
| Regeneron Pharmaceuticals Inc | 3,702,995 | 2.65% |
| Geode Capital Management, LLC | 2,851,472 | 2.04% |
| UBS Group AG | 2,689,486 | 1.92% |
Insider activity · 90d
13 buys / 2 sells · ratio 6.5 · Finnhub
- Dulac Edward J III SELL 156,286 @ $18.00
- Dube Michael P SELL 66,886 @ $16.78
- GOODMAN JESSE BUY 13,300
- GOODMAN JESSE BUY 33,559
- Keresty Georgia BUY 13,300
- Keresty Georgia BUY 41,083
- Bhanji Muna BUY 13,300
- Bhanji Muna BUY 36,403
- CHASE WILLIAM J BUY 13,300
- CHASE WILLIAM J BUY 143,893
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-06 | 4 | view · |
| 4 | 2026-07-06 | 4 | view · |
| 8-K | 2026-06-15 | 8-K | view · |
| 4 | 2026-06-10 | 4 | view · |
| 4 | 2026-06-10 | 4 | view · |
| 4 | 2026-06-10 | 4 | view · |
| 4 | 2026-06-10 | 4 | view · |
| 4 | 2026-06-10 | 4 | view · |
| 4 | 2026-06-10 | 4 | view · |
| 4 | 2026-06-10 | 4 | view · |
| 8-K | 2026-06-10 | 8-K | view · |
| 10-Q | 2026-05-11 | 10-Q | view · |
| 8-K | 2026-05-11 | 8-K | view · |
| 8-K | 2026-04-30 | 8-K | view · |
| DEF 14A | 2026-04-30 | DEF 14A | view · |
| 8-K | 2026-04-27 | 8-K | view · |
| 8-K | 2026-04-10 | 8-K | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 8-K | 2026-03-02 | 8-K | view · |
| 10-K | 2026-02-26 | 10-K | view · |
| 8-K | 2026-02-26 | 8-K | view · |
| 8-K | 2026-01-27 | 8-K | view · |
| 8-K | 2026-01-09 | 8-K | view · |
| 4 | 2026-01-07 | 4 | view · |
| 4 | 2026-01-07 | 4 | view · |
| 4 | 2026-01-07 | 4 | view · |
| 4 | 2026-01-07 | 4 | view · |
| 4 | 2026-01-07 | 4 | view · |
| 4 | 2026-01-07 | 4 | view · |
| 4 | 2026-01-07 | 4 | view · |
| 4 | 2026-01-07 | 4 | view · |
| 4 | 2025-12-12 | 4 | view · |
| 8-K | 2025-11-10 | 8-K | view · |
| 10-Q | 2025-11-06 | 10-Q | view · |
| 8-K | 2025-11-06 | 8-K | view · |
| 8-K | 2025-10-29 | 8-K | view · |
| 8-K | 2025-10-27 | 8-K | view · |
| 4 | 2025-10-03 | 4 | view · |
| 4 | 2025-10-03 | 4 | view · |
| 8-K | 2025-09-25 | 8-K | view · |
| 4 | 2025-08-22 | 4 | view · |
| 10-Q | 2025-08-07 | 10-Q | view · |
| 8-K | 2025-08-07 | 8-K | view · |
| 4 | 2025-07-25 | 4 | view · |
| 4 | 2025-07-03 | 4 | view · |
| 4 | 2025-07-03 | 4 | view · |
| 4 | 2025-07-02 | 4 | view · |
| 4 | 2025-06-18 | 4 | view · |
| 8-K | 2025-06-16 | 8-K | view · |
| 4 | 2025-06-13 | 4 | view · |
| 4 | 2025-06-13 | 4 | view · |
| 4 | 2025-06-13 | 4 | view · |
| 4 | 2025-06-13 | 4 | view · |
| 4 | 2025-06-13 | 4 | view · |
About NTLA
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the deve…
Options picks · NTLA
ITM + OTM ideas from the latest scanLoading…
Congress trades · NTLA
STOCK Act disclosuresLoading…
SEC filings & insiders · NTLA
EDGAR · liveLoading…
Holders · NTLA
Institutions & insider activityLoading…